With 13.1% CAGR, Breast Cancer Therapeutics Market Size to Surpass Around USD 55.27 Billion by 2027
08 nov. 2022 05h36 HE
|
Fortune Business Insights
Pune, India, Nov. 08, 2022 (GLOBE NEWSWIRE) -- The global breast cancer therapeutics market is set to gain impetus from the ongoing research and developments to come up with state-of-the-art drugs....
Modifi Bio Receives $2.4 Million Award from National Cancer Institute to Advance Innovative Precision Oncology Platform
25 oct. 2022 08h00 HE
|
Modifi Biosciences
NEW HAVEN, Conn., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Modifi Biosciences, a leader in direct DNA modification developing novel cancer therapeutics, has been selected by the National Cancer Institute...
Cancer Therapeutics and Biotherapeutics Market Size to Surpass US$ 339.44 Bn by 2030
03 mai 2022 10h00 HE
|
Precedence Research
Ottawa, May 03, 2022 (GLOBE NEWSWIRE) -- The global cancer therapeutics and biotherapeutics market was estimated at US$ 161.76 billion in 2021. The government and big market participants are heavily...
Qualigen Therapeutics Secures Worldwide Rights to G4-Selective Transcription Inhibitors from University College London to Develop as Cancer Therapeutics
18 janv. 2022 09h15 HE
|
Qualigen Therapeutics, Inc.
Preclinical Therapeutic Program to Be Initially Focused on Pancreatic Cancer CARLSBAD, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology...
Kernal Biologics Presenting Results at the 9th Annual mRNA Health Conference
09 nov. 2021 02h00 HE
|
Kernal Biologics, Inc.
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Kernal Biologics, Inc. (Kernal Bio) — an early-development-stage mRNA-technology company developing cancer therapeutics designed to improve...
Kernal Biologics Enters Development Phase Reaching Critical Milestones for its First mRNA-Based Cancer-Therapeutic Product
22 juil. 2021 08h00 HE
|
Kernal Biologics, Inc.
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Kernal Biologics, Inc. (Kernal Bio) — an early-development-stage mRNA-technology company developing cancer therapeutics designed to improve...
bioAffinity Technologies Joins National Lung Cancer Roundtable
11 oct. 2019 11h00 HE
|
bioAffinity Technologies, Inc.
SAN ANTONIO, Texas, Oct. 11, 2019 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biotech company, today announced that it has been accepted as a member of the American Cancer...
CFN Media's Exclusive Interview with Pascal Biosciences
08 nov. 2018 08h30 HE
|
CFN Media
SEATTLE, Nov. 08, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry,...
bioAffinity Technologies Welcomes Peter S. Knight to Board of Directors
14 mai 2018 10h00 HE
|
bioAffinity Technologies, Inc.
SAN ANTONIO, May 14, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biomedical company advancing breakthrough cancer diagnostics and therapeutics, is pleased to welcome Peter S....
Onconova Therapeutics, Inc. to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co., LLC
26 avr. 2017 08h30 HE
|
Onconova Therapeutics
NEWTOWN, Pa., April 26, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to...